Αρχική World News FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory... World News FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma Από Ogkologos - 27 Μαρτίου, 2025 764 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation AI for early cancer detection: where are we now? MOST POPULAR Truck Driver Saves People From Bus Fire On Christmas Eve 31 Δεκεμβρίου, 2021 ¿Qué es la escasez de medicamentos y cómo puede afectar a... 30 Ιουνίου, 2023 Transforming optimism: finding new ways to treat rare cancers 27 Ιανουαρίου, 2021 FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive Gastric Adenocarcinomas 20 Ιανουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Man Met A Stranger At A Bar Who Was In Need... ‘Jeopardy!’ Legend James Holzhauer Donates Portion Of Winnings To Cancer Walk... FDA Grants Accelerated Approval to Ponatinib with Chemotherapy for Newly Diagnosed... Nirogacestat Shows Significant Benefit in Patients with Progressing Desmoid Tumours